J&J files U.S. application for IV selexipag for high blood pressure in lung arteries

Johnson & Johnson (NYSE:JNJ) unit The Janssen Pharmaceutical Companies has submitted a marketing application to the FDA seeking approval of an intravenous (IV) formulation of Uptravi (selexipag) for the treatment of pulmonary arterial hypertension (PAH), a rare disorder characterized by high blood pressure in the arteries of the lungs, in certain adults who are currently prescribed oral Uptravi but are temporarily unable to take the tablets.

The FDA OK'd the oral formulation for PAH in December 2015.

https://seekingalpha.com/news/3618313-j-and-j-files-u-s-application-for-iv-selexipag-for-high-blood-pressure-in-lung-arteries